American Society of Hematology

Figure 7.

$Figure 7. In vivo presence of T1 and T2 populations after allogeneic BMT. (A) Absolute numbers of splenic T1 or T2 cells after BMT. CD3/CD28-generated T1 and T2 populations were derived from Ly5.1 B6 donors and administered to lethally irradiated CB6F1 hosts inoculated with TSA breast cancer cells. Spleens were harvested and counted at days 5 and 14 after BMT, and the fraction of CD45.1+ cells was determined by flow cytometry with subsequent calculation of absolute splenic T1 or T2 cells (n = 3 per BMT group; mean ± SEM shown). (B) Absolute number of splenic CD8+ T1 or T2 cells after BMT. Samples from the experiment described in panel A were additionally evaluated by 3-color flow cytometry for CD8+/CD45.1+ cells. (n = 3 per BMT group; mean ± SEM shown).$

In vivo presence of T1 and T2 populations after allogeneic BMT. (A) Absolute numbers of splenic T1 or T2 cells after BMT. CD3/CD28-generated T1 and T2 populations were derived from Ly5.1 B6 donors and administered to lethally irradiated CB6F1 hosts inoculated with TSA breast cancer cells. Spleens were harvested and counted at days 5 and 14 after BMT, and the fraction of CD45.1⁺ cells was determined by flow cytometry with subsequent calculation of absolute splenic T1 or T2 cells (n = 3 per BMT group; mean ± SEM shown). (B) Absolute number of splenic CD8⁺ T1 or T2 cells after BMT. Samples from the experiment described in panel A were additionally evaluated by 3-color flow cytometry for CD8⁺/CD45.1⁺ cells. (n = 3 per BMT group; mean ± SEM shown).

This Feature Is Available To Subscribers Only